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Abstract
Background:  Countries are increasingly devoting significant resources to creating or
strengthening research ethics committees, but there has been insufficient attention to assessing
whether these committees are actually improving the protection of human research participants.
Discussion:  Research ethics committees face numerous obstacles to achieving their goal of
improving research participant protection. These include the inherently amorphous nature of
ethics review, the tendency of regulatory systems to encourage a focus on form over substance,
financial and resource constraints, and conflicts of interest. Auditing and accreditation programs
can improve the quality of ethics review by encouraging the development of standardized policies
and procedures, promoting a common base of knowledge, and enhancing the status of research
ethics committees within their own institutions. However, these mechanisms focus largely on
questions of structure and process and are therefore incapable of answering many critical questions
about ethics committees' actual impact on research practices.
The first step in determining whether research ethics committees are achieving their intended
function is to identify what prospective research participants and their communities hope to get
out of the ethics review process. Answers to this question can help guide the development of
effective outcomes assessment measures. It is also important to determine whether research ethics
committees' guidance to investigators is actually being followed. Finally, the information developed
through outcomes assessment must be disseminated to key decision-makers and incorporated into
practice. This article offers concrete suggestions for achieving these goals.
Conclusion: Outcomes assessment of research ethics committees should address the following
questions: First, does research ethics committee review improve participants' understanding of the
risks and potential benefits of studies? Second, does the process affect prospective participants'
decisions about whether to participate in research? Third, does it change participants' subjective
experiences in studies or their attitudes about research? Fourth, does it reduce the riskiness of
research? Fifth, does it result in more research responsive to the local community's self-identified
needs? Sixth, is research ethics committees' guidance to researchers actually being followed?
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Background
Many countries are investing significant resources in creat-
ing or strengthening "research ethics committees" (RECs)
to review proposed research involving human partici-
pants, either within research institutions, as part of gov-
ernmental agencies, or in the private sector. Implicit in
these efforts is the assumption that REC review will result
in research that better complies with applicable ethical
principles. Yet, surprisingly little attention has been
devoted to testing the empirical validity of this assump-
tion. As a result, it is possible that countries are wasting
scarce financial and human resources on processes that do
not result in any real protections for research participants
or their communities. In addition, without a system for
evaluating RECs' actual impact, opportunities for remedy-
ing correctable problems with RECs are likely to be
missed.
The importance of evaluating the effectiveness of RECs
should be obvious. Yet, despite the emphasis on quality
assessment in other areas of health care, "there has been
near silence on the possibility of applying quality assess-
ment techniques to ethics practices [1]." While the need
for quality assessment in research ethics is beginning to
receive greater attention [2], the focus has largely been on
evaluating the quality of the deliberations that take place
in RECs' meetings, as opposed to the impact of those
deliberations on the research process itself.
Existing mechanisms for evaluating RECs are primarily
limited to governmental or private auditing and accredita-
tion programs. While both auditing and accreditation can
make important contributions to the quality of research
review systems, they are incapable of answering many crit-
ical questions about RECs' impact on research practices.
Moreover, comprehensive auditing and accreditation pro-
grams require an investment of human and financial
resources that is unfeasible for many low- and middle-
income countries. In this article, we look beyond auditing
and accreditation to consider other mechanisms for
assessing and improving the quality of RECs' work.
While the focus of this article is RECs in low- and middle-
income countries, the issues it addresses are relevant eve-
rywhere. In the United States, for example, an increasing
chorus of critics has charged that the process of research
ethics review imposes substantial costs for the research
enterprise that exceed any benefits to research participants
[3,4]. Determining whether the costs of ethics review are
in fact justified requires a better understanding of the
impact of ethics review on how research is actually per-
formed.
Discussion
The Increasing Role of REC Review
REC review is a cornerstone of international guidelines on
research with human participants. For example, the Coun-
cil for International Organizations of Medical Sciences
(CIOMS) states that "all proposals to conduct research
involving human subjects must be submitted for review
and approval to one or more independent ethical and sci-
entific review committees [5]." Similar obligations appear
in guidelines issued by the International Conference on
Harmonization (ICH) [6], the Council of Europe [7], and
UNESCO [8]. These guidelines require RECs to ensure
that the risks of proposed studies are reasonable in rela-
tion to the anticipated benefits, that the investigators have
adequate plans for obtaining participants' informed con-
sent, and that other ethical issues, such as confidentiality
and equitable participant selection, have been adequately
addressed.
However, these international guidelines are not legally
binding in countries that have not chosen to adopt them.
Thus, whether REC review is required for any particular
study depends on the requirements of national laws and
policies. In the United States and many other wealthy
countries, review by an REC is mandatory for most
research involving human participants [9]. By contrast, in
many low-income countries, there are no laws requiring
REC oversight, or laws that exist are incomplete or under-
enforced [10,11]. When research is conducted in collabo-
ration with foreign research sponsors, some type of ethics
review may be required by the laws of the sponsor's coun-
try, but such laws do not always require review by local
RECs. For example, while the United States Food and
Drug Administration (FDA) has extensive regulations gov-
erning REC review for clinical trials conducted pursuant to
an Investigational New Drug Application (IND), those
regulations do not apply to foreign trials not conducted
pursuant to an IND. Instead, the FDA will accept data
from non-IND foreign trials as long as the trial "conforms
to the ethical principles contained in the Declaration of
Helsinki [12]," which contains only very general provi-
sions on ethical review.
In recent years, however, many low and middle-income
countries have begun to pay greater attention to develop-
ing or strengthening RECs. For example, at the 2004 Min-
isterial Summit on Health Research in Mexico City, health
officials from 58 countries called for national govern-
ments to adopt regulations providing for the "ethical
oversight" of research [13]. In many African countries,
governments have enacted, or are in the process of enact-
ing, legislation requiring REC review of research involving
human participants [14,15]. Even without a governmen-
tal mandate, many research institutions in resource-poor
countries have created RECs on their own initiative, some-BMC Medical Ethics 2008, 9:6 http://www.biomedcentral.com/1472-6939/9/6
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times in collaboration with other countries [11] or with
non-governmental organizations [16].
One reason for this increasing interest in RECs is that
research sponsors are conducting more of their studies in
low and middle-income countries, both because it is less
expensive [17] and because it has become increasingly dif-
ficult to find a sufficient number of qualified participants
in the sponsors' home countries [18]. In addition, a few
highly-publicized controversies have led to greater atten-
tion to the potential for exploitation in the context of
international collaborative research. For example, a law-
suit currently pending against the foreign sponsors of a
Nigerian study of an anti-meningitis drug alleges that chil-
dren in the control group were not given adequate medi-
cations, that parents were not told that effective treatment
for meningitis was readily available outside of the study,
and that documents claiming that the study had been
approved by a Nigerian ethics review process were forged
[19]. Publicity about cases like this has given sponsors a
greater incentive to support the development of local
RECs.
Challenges for REC Review
For a country that lacks any research oversight system, cre-
ating a review process – any review process – is likely to
have a positive impact. For example, requiring researchers
to submit their protocols to RECs creates an incentive for
researchers to actually have written protocols. Requiring
them to document the informed consent process reduces
the likelihood that individuals will be enrolled in studies
without even being asked for consent. In other words,
simply requiring prior approval to do research should
help weed out the truly egregious cases of researcher mis-
conduct.
Designing a system to evaluate the ethical acceptability of
studies that pass this minimal screening function raises
more challenging conceptual and practical difficulties. On
the most basic level, the very concept of "ethics review" is
inherently ambiguous, particularly in the critical area of
risk-benefit assessment. Identifying the risks and potential
benefits of research, and determining whether the balance
between them is "reasonable," depend not only on scien-
tific arguments but also on value judgments that usually
have no clearly right or wrong resolution. In the absence
of objective standards, RECs must rely on individuals' dis-
cretionary judgments, an approach that risks overempha-
sizing the personal values and biases of the individuals
who happen to be serving on the committee [20]. In addi-
tion, the discretionary nature of risk-benefit assessment
increases the potential for inconsistent decision-making,
not only between different RECs but also within a single
REC as it confronts similar issues from meeting to meet-
ing. Of course, in a pluralistic society, absolute uniformity
in ethical decision-making is neither realistic nor desira-
ble. However, widespread inconsistency, particularly
within a single REC, creates the impression that ethical
standards are being applied in an arbitrary manner.
Some RECs deal with the amorphous nature of risk-bene-
fit assessment by spending most of their time on detail-
oriented questions that appear more susceptible to objec-
tive resolution, such as parsing the wording of informed
consent forms [21]. Unfortunately, while rewriting con-
sent forms is undoubtedly important in some situations,
when it becomes the primary focus of ethics review larger
ethical questions can easily become lost. Indeed, some
critics charge that an obsessive focus on rewriting consent
forms can actually undermine the protection of research
participants, as it may simply result in longer and more
confusing forms that participants will be less likely to
understand [22].
On a more practical level, the effectiveness of REC review
is often hampered by insufficient financial and human
resources [15]. These limitations make it difficult to create
committees with sufficient expertise and diversity, to pro-
vide funding for staff support, and to provide training for
committee members. Ensuring the independence of RECs
can also be a significant challenge. For example, in insti-
tutional-based RECs, committee members may be asked
to vote on proposals submitted by colleagues who are per-
sonal friends, or by senior members of their department
who control decisions about promotion and tenure.
The problem of independence is particularly acute for
RECs in low and middle-income countries. Because such
countries may depend on the financial or other benefits
associated with foreign-sponsored research, RECs may be
under explicit or implicit pressure not to reject research
protocols or to insist on changes that might lead sponsors
to take their studies elsewhere [23]. Adding to these prob-
lems is the fact that, in many resource-poor countries,
RECs must carry out their work in the absence of a well-
developed regulatory structure or a culture of compliance
with administrative and procedural requirements.
Existing Oversight Mechanisms for RECs
In many countries, REC oversight is the responsibility of
national governmental agencies. In the United States, for
example, the Food and Drug Administration (FDA) and
the Office for Human Research Protections (OHRP) are
responsible for overseeing most RECs in the country
(where they are known as institutional review boards, or
IRBs). These agencies conduct site visits of selected pro-
grams, either without cause or in response to a specific
problem, and they also have less formal procedures for
responding to individual complaints. OHRP's site visitsBMC Medical Ethics 2008, 9:6 http://www.biomedcentral.com/1472-6939/9/6
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include a review of 20–35 randomly-selected protocols
and meeting minutes dating back one to four years [24].
Some countries require RECs to go through a formal proc-
ess of governmental accreditation. For example, in New
Zealand, the Health Research Council accredits research
ethics committees. If a study proceeds without the
approval of an accredited ethics committee, participants
who suffer injuries may not be eligible for compensation
from the country's no-fault compensation system [25].
Approval by an accredited committee is also necessary for
researchers to obtain access to data held by the New Zea-
land Health Information Service database [26]. Accredita-
tion usually involves a combination of self-assessment
and external reviews, focusing on issues like committee
membership, operating procedures, and the documenta-
tion of meetings [27].
There are also voluntary accreditation programs for RECs.
The largest of these is run by the Association for the
Accreditation of Human Research Protection Programs
(AAHRPP) [28]. Obtaining AAHRPP accreditation is an
intensive process that usually takes 12–18 months,
including both document reviews and a 2–4 day site visit
during which dozens of persons involved in all aspects of
the research program are individually interviewed. In
order to be accredited, programs must demonstrate not
only that they are in compliance with all applicable regu-
latory requirements, but also that they have developed
guidelines for addressing certain issues not expressly cov-
ered by the regulations (e.g., standards governing the par-
ticipation of decisionally incapacitated persons in
research). While most of the programs that have received
AAHRPP accreditation are located in the United States,
AAHRPP has also accredited programs in Canada, Singa-
pore, and South Korea.
In addition to AAHRPP, the Strategic Initiative for Devel-
oping Capacity in Ethical Review (SIDCER), a network of
local and regional ethics organizations working with sev-
eral United Nations organizations, has established a vol-
untary "recognition" program for RECs. The program
offers recognition to RECs that demonstrate that they "(1)
have a structure and composition appropriate to the
amount and nature of research being conducted; (2) have
appropriate management and operational procedures; (3)
review protocols in a timely fashion according to estab-
lished procedure; (4) adequately and effectively commu-
nicate decisions to investigators; and (5) have appropriate
practices regarding documentation and archiving [29]."
The SIDCER program includes educational components
designed to support RECs' progress toward recognition.
Committees from China, Philippines, South Korea, Thai-
land and Taiwan have already been recognized through
this process.
Finally, some mechanisms also exist for evaluating the
qualifications of individual REC members. For example, a
non-profit organization in the United States called Public
Responsibility in Medicine and Research (PRIMR) offers a
certification program for IRB members and staff, which
"evaluates and validates individuals' knowledge of ethical
principles, historical events, regulatory requirements, and
operational and functional issues relating to IRBs and
other human subjects protection programs [30]." Persons
who pass the certification test are authorized to include
the acronym CIP ("certified IRB professional") in their
professional titles.
All of these mechanisms can make important contribu-
tions to the quality of the ethics review process. Auditing
and accreditation programs encourage RECs to develop
standardized policies and procedures, which helps pro-
mote the consistent application of ethical principles. They
also provide a means for checking whether RECs are actu-
ally adhering to the policies and procedures they claim to
be following. Private accreditation programs have the
added advantage of encouraging RECs to develop policies
and procedures for issues that are insufficiently addressed
at the regulatory level. Certification programs for REC
members can complement the accreditation process by
promoting a common base of knowledge about applica-
ble ethical and regulatory principles. Moreover, both
accreditation and certification are likely to enhance the
status of RECs within their own institutions, which may
make it easier for RECs to gain necessary institutional
resources.
However, these mechanisms also have inherent limita-
tions. Most significantly, they focus primarily on ques-
tions about RECs' structure and process, such as how
committees are constituted, whether their standard oper-
ating procedures are complete, and whether the process of
protocol review is adequately documented [31]. One dan-
ger with this focus is that it may exacerbate RECs' ten-
dency to emphasize form over substance. A recent study of
OHRP enforcement activities highlights this problem; it
found that "the agency continues to nitpick consent
forms, depends upon (and demands) extensive documen-
tation of compliance activities, and finds the remedy for
most problems to be 'more' – review of studies, internal
monitoring procedures, education, forms." The result of
this focus, the authors conclude, is "a culture of red tape
rather than a culture of ethics [24]."
A larger concern with an exclusive focus on structure and
process is that it is incapable of answering the bottom-line
question: whether REC review actually protects the rights
and interests of research participants and their communi-
ties. For example, the fact that an REC has documented
that it has considered a protocol's risks and potential ben-BMC Medical Ethics 2008, 9:6 http://www.biomedcentral.com/1472-6939/9/6
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efits does not mean that it has done a good job identifying
or weighing these factors. Nor does it show that studies
that are approved by the committee have more favorable
risk-benefit profiles than those that are turned down. Sim-
ilarly, the fact that an REC has concluded that a consent
form contains all relevant information does not mean
that prospective participants who read the form will actu-
ally understand or absorb the information, or that it will
have any appreciable impact on their decision-making
process. In short, all that auditing and accreditation pro-
grams tell us is whether RECs are carrying out the specific
tasks that have been assigned to them. While this is cer-
tainly an important question, even an affirmative answer
does not prove that an REC system "works."
Integrating Quality Assurance Principles into REC 
Assessment
Principles developed through decades of experience with
quality assurance and improvement in other areas of
health care can guide the development of effective over-
sight programs for RECs. The most basic of these princi-
ples is that, before the quality of any program or service
can be evaluated, the relevant elements of quality must be
identified with precision. Quality is a multifaceted con-
cept, including factors like the technical competence with
which an activity is performed, the impact of the activity
on morbidity and mortality, and the activity's cost effec-
tiveness. Choosing which of these goals to emphasize
"requires a commitment to finding out what patients and
the community need, want, and expect from the health
service [32]."
Thus, the first step in developing a comprehensive quality
assurance program for RECs should be to identify what
prospective research participants and their communities
hope to get out of the ethics review process. For example,
is the concern that people are being misled into enrolling
in studies in which they would have refused to participate
had they known what they were getting into? If so, it
would be useful to know whether REC review has an
impact on the number of people who go through the
informed consent process and then decide not to partici-
pate. Alternatively, the goal might be to increase the extent
to which participants feel respected in the research proc-
ess, regardless of whether they end up making different
decisions about participating [33]. In that case, we should
try to find out whether REC review actually affects partici-
pants' subjective experiences in studies or their attitudes
about research. Both of these questions, of course, depend
on first determining whether prospective participants
understand the information that has been presented to
them in the consent process. While some research related
to this question has already been conducted [34], assess-
ing participants' understanding has not yet been systemat-
ically integrated into the process of REC oversight.
Similar questions can be raised about the process of risk-
benefit assessment. For example, is REC review considered
important because of a concern that research is generally
"too risky"? If so, we should look at whether adopting an
REC process actually affects the riskiness of research – per-
haps by investigating whether REC review has an impact
on the incidence of adverse events. Or is the concern that,
without RECs, research might not address the health
needs of the local community? In that case, we might
want to see whether studies approved by an REC are in
fact consistent with the local community's needs.
These broad outcome-oriented questions will not always
be easy to answer. Outcomes assessment is one of the
trickiest areas of quality assurance; numerous confound-
ing variables can undermine the validity of simple before-
and-after comparisons. For example, in many health care
programs, outcome measurements such as mortality rates
can be useful indicators of the quality of services, but they
may also reflect "differences in the resources available, the
risk factors of the patient group, data accuracy, and chance
alone [35]." Likewise, an increase in adverse events fol-
lowing the creation of an REC does not necessarily mean
that the REC is a failure; it may instead reflect a shift
towards studies related to more serious conditions, where
the greater potential benefits justify a higher degree of risk.
Developing methodologically sound measures of assess-
ing REC outcomes is an area ripe for further research.
Another important dimension of quality assurance that
existing oversight efforts do not incorporate is the basic
question of whether RECs' guidance to researchers is actu-
ally being followed. For example, do researchers really uti-
lize the informed consent processes described in their
protocols, or do they simply hand prospective partici-
pants a consent form and ask them to sign it? RECs could
adopt a variety of relatively simple methods to generate
information relevant to this question, such as soliciting
feedback from prospective participants through question-
naires or suggestion boxes. Or, borrowing a practice used
in other health care settings, they could use actors to play
the role of prospective research participants, in order to
evaluate how people are treated when they go through the
informed consent process [32]. While these measures
would require some additional resources, they are far less
expensive than many other methods of quality assurance
– for example, going through an 18-month process of
obtaining accreditation.
Finally, and most importantly, a "monitoring system is
not an end in itself [36];" the information generated
through an assessment process must be used to stimulate
improvements in practice. Doing this requires a commit-
ment to a process of continuous quality improvement, in
which information from the assessment process is dissem-BMC Medical Ethics 2008, 9:6 http://www.biomedcentral.com/1472-6939/9/6
Page 6 of 7
(page number not for citation purposes)
inated to key decision-makers and incorporated into prac-
tice. Thus, an REC might ask researchers involved in
approved studies to report back about the most common
questions asked by prospective participants during the
informed consent process, and then use this information
to change the way they evaluate informed consent forms
in the future. Global or regional meetings of RECs, as well
as online discussion forums, can provide valuable oppor-
tunities for sharing information and identifying and pro-
moting best practices. In addition to disseminating
information among REC members, it is important to
share findings about REC practices with external audi-
ences like administrative authorities and community
leaders.
Conclusion
Low and middle-incomes countries are increasingly dem-
onstrating their capacity to put into practice concrete
mechanisms for enforcing ethical requirements. Interna-
tional cooperation has been a key factor in this progress.
However, it is not clear whether these systems have led to
substantial improvements in the way that research is actu-
ally conducted. It is time to look beyond the basic ques-
tion of whether RECs are complying with existing
standards to the larger question of whether compliance
with these standards is having the desired results.
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